Your browser is no longer supported. Please, upgrade your browser.
ENTA Enanta Pharmaceuticals, Inc. daily Stock Chart
Enanta Pharmaceuticals, Inc.
Index- P/E600.68 EPS (ttm)0.07 Insider Own0.40% Shs Outstand20.02M Perf Week-1.97%
Market Cap876.56M Forward P/E- EPS next Y-3.55 Insider Trans0.00% Shs Float17.72M Perf Month0.94%
Income2.40M PEG- EPS next Q-0.54 Inst Own93.20% Short Float11.75% Perf Quarter-12.86%
Sales150.20M P/S5.84 EPS this Y-39.70% Inst Trans0.99% Short Ratio12.36 Perf Half Y-19.05%
Book/sh24.00 P/B1.83 EPS next Y-298.90% ROA0.50% Target Price67.57 Perf Year-26.36%
Cash/sh18.51 P/C2.37 EPS next 5Y- ROE0.50% 52W Range38.40 - 67.88 Perf YTD-29.02%
Dividend- P/FCF29.51 EPS past 5Y4.30% ROI8.10% 52W High-35.40% Beta0.60
Dividend %- Quick Ratio17.30 Sales past 5Y33.90% Gross Margin- 52W Low14.19% ATR1.48
Employees132 Current Ratio17.30 Sales Q/Q-57.90% Oper. Margin-10.20% RSI (14)40.98 Volatility3.32% 3.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-313.70% Profit Margin1.60% Rel Volume1.67 Prev Close43.67
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout0.00% Avg Volume168.41K Price43.85
Recom2.40 SMA20-2.79% SMA50-6.48% SMA200-13.01% Volume280,473 Change0.41%
Aug-28-20Resumed ROTH Capital Buy $104
Aug-26-20Initiated Piper Sandler Overweight $87
Jul-27-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $70
Mar-17-20Upgrade Robert W. Baird Neutral → Outperform $60
Nov-22-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19Downgrade JP Morgan Neutral → Underweight $86 → $57
May-24-19Initiated Wolfe Research Outperform $117
Apr-23-19Upgrade Berenberg Hold → Buy $80 → $120
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated Barclays Underweight $16 → $18
Oct-23-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Oct-23-15Downgrade Barclays Equal Weight → Underweight $45 → $16
Aug-07-15Reiterated Barclays Equal Weight $35 → $45
Oct-12-20 01:27PM  
Sep-28-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 07:01AM  
Aug-28-20 06:15AM  
Aug-26-20 09:42AM  
Aug-20-20 07:00AM  
Aug-07-20 09:28AM  
Aug-05-20 01:31AM  
Aug-04-20 06:35PM  
Aug-03-20 07:02AM  
Jul-28-20 12:32PM  
Jul-17-20 01:41PM  
Jul-09-20 07:01AM  
Jun-29-20 07:00AM  
Jun-23-20 12:23PM  
Jun-11-20 07:02AM  
Jun-04-20 10:20PM  
May-23-20 09:58AM  
May-14-20 08:53AM  
May-12-20 07:30AM  
May-09-20 09:43PM  
May-07-20 12:01AM  
May-06-20 06:45PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-17-20 10:19AM  
Mar-26-20 04:05PM  
Mar-13-20 07:00AM  
Mar-06-20 07:05AM  
Mar-04-20 08:09AM  
Feb-12-20 12:18AM  
Feb-06-20 05:15PM  
Feb-05-20 04:11PM  
Feb-03-20 07:27AM  
Jan-30-20 12:31PM  
Jan-24-20 07:30AM  
Jan-14-20 05:30AM  
Jan-09-20 07:30AM  
Jan-04-20 08:44AM  
Dec-30-19 07:30AM  
Dec-11-19 11:25AM  
Dec-09-19 07:38AM  
Dec-07-19 11:24PM  
Nov-22-19 08:18AM  
Nov-21-19 05:15PM  
Nov-17-19 08:42AM  
Nov-14-19 10:30AM  
Nov-11-19 10:21AM  
Nov-05-19 04:00PM  
Oct-27-19 10:29PM  
Oct-21-19 04:00PM  
Oct-12-19 10:03AM  
Oct-03-19 07:30AM  
Sep-30-19 04:48PM  
Sep-26-19 04:16PM  
Sep-25-19 04:28PM  
Sep-12-19 09:48AM  
Sep-10-19 07:30AM  
Aug-21-19 07:30AM  
Aug-19-19 02:54PM  
Aug-13-19 01:24PM  
Aug-07-19 12:37PM  
Aug-06-19 05:55PM  
Aug-02-19 08:51AM  
Jul-30-19 10:38AM  
Jul-15-19 07:30AM  
Jul-11-19 09:00AM  
Jul-08-19 07:30AM  
Jun-14-19 02:06PM  
Jun-10-19 04:00PM  
May-30-19 08:00AM  
May-15-19 08:23PM  
May-14-19 04:01PM  
May-07-19 09:00PM  
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gardiner Nathaniel S.Sr. VP & General CounselAug 05Option Exercise30.001,66649,98029,271Aug 06 04:38 PM
MELLETT PAUL JTreasurer and CFOMay 05Option Exercise1.211,7402,10042,824May 07 05:35 PM
Gardiner Nathaniel S.Sr. VP & General CounselMar 12Option Exercise30.003,00090,00027,605Mar 16 06:27 PM
MELLETT PAUL JTreasurer and CFOJan 02Sale60.8810,000608,80040,054Jan 06 06:17 PM
Gardiner Nathaniel S.Sr. VP & General CounselNov 22Option Exercise31.421,59250,02119,739Nov 25 05:01 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.